Quijano-Rubio, Clara
Silginer, Manuela
Weller, Michael
Funding for this research was provided by:
Oncosuisse (KLS-3814-02-2016)
University of Zurich
Article History
Received: 18 July 2022
Accepted: 17 September 2022
First Online: 10 November 2022
Statements and declarations
:
: C.Q.R. and M.S. report no conflicts of interest. M.W. has received research grants from Apogenix, Merck, Sharp & Dohme, Merck (EMD), Philogen and Quercis, and honoraria for lectures or advisory board participation or consulting from Adastra, Bayer, Bristol Meyer Squibb, Medac, Merck, Sharp & Dohme, Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen and y-Mabs.
: All animal studies were conducted in accordance with the Swiss federal act on animal protection. All experiments were approved by the cantonal veterinary office under the animal license numbers ZH178/2016 and ZH109/2020.